Policy Summary
Medical disclaimer
This site provides informational content only and does not provide medical advice, diagnosis, prescribing, pharmacy services, or emergency care.
Key standards
This site provides informational content only and does not provide medical advice, diagnosis, prescribing, pharmacy services, or emergency care.
Compounded tirzepatide and compounded semaglutide are not FDA-approved as finished drugs. They may be prescribed only when a licensed provider determines they are clinically appropriate and legally permissible for an individual patient. Brand-name medications such as Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved products and should not be treated as identical to compounded medications.
Frequently asked questions
Can I request a correction?
Yes. Use the contact page or correction policy to request a source or pricing correction.
Is this medical advice?
No. The site is informational only and does not replace licensed medical advice.
Sources
- FDA GLP-1 compounding policy clarification (Regulator)
- FDA Compounding and the FDA: Questions and Answers (Regulator)
- FDA 503B bulks list proposal for GLP-1 drugs (Regulator)
- Zepbound prescribing information (Label)
- Wegovy prescribing information (Label)
- NexLife tirzepatide pricing page (Provider pricing)
- NexLife FAQ pricing page (Provider pricing)
- NexLife semaglutide pricing page (Provider pricing)